- Home
- BFST vs FBRX Comparison
BFST vs FBRX Comparison
Compare BFST & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BFST | FBRX |
|---|---|---|
| Founded | 2006 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 899.4M |
| IPO Year | 2014 | 2017 |
Fundamental Metrics
Financial Performance| Metric | BFST | FBRX |
|---|---|---|
| Price | $32.25 | $76.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $32.75 | ★ $67.00 |
| AVG Volume (30 Days) | 222.0K | ★ 1.9M |
| Earning Date | 04-27-2026 | 05-14-2026 |
| Dividend Yield | ★ 2.23% | N/A |
| EPS Growth | 23.45 | ★ 61.30 |
| EPS | ★ 1.37 | N/A |
| Revenue | ★ $10,704,000.00 | $36,000.00 |
| Revenue This Year | $22.71 | N/A |
| Revenue Next Year | $5.02 | N/A |
| P/E Ratio | $23.56 | ★ N/A |
| Revenue Growth | ★ 1.20 | N/A |
| 52 Week Low | $22.56 | $10.18 |
| 52 Week High | $32.53 | $77.20 |
Technical Indicators
Market Signals| Indicator | BFST | FBRX |
|---|---|---|
| Relative Strength Index (RSI) | 64.99 | 84.48 |
| Support Level | $29.48 | $26.51 |
| Resistance Level | $32.39 | $77.20 |
| Average True Range (ATR) | 0.53 | 0.18 |
| MACD | -0.02 | -1.16 |
| Stochastic Oscillator | 82.95 | 57.93 |
Price Performance
Historical ComparisonAbout BFST Business First Bancshares Inc.
Business First Bancshares Inc is a bank holding company. The company's services include personal and commercial banking, treasury management, and wealth solutions. It provides a range of financial services to small-to-midsized businesses and professionals. The company generates the majority of its revenues from interest income on loans, customer service and loan fees, and interest income from securities.
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.